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Abstract: The interplay between free radicals, antioxidants, and co-factors is important in 
maintaining health, aging and age-related diseases. Free radicals induce oxidative stress, which 
is balanced by the body’s endogenous antioxidant systems with an input from co-factors, 
and by the ingestion of exogenous antioxidants. If the generation of free radicals exceeds the 
protective effects of antioxidants, and some co-factors, this can cause oxidative damage which 
accumulates during the life cycle, and has been implicated in aging, and age dependent dis-
eases such as cardiovascular disease, cancer, neurodegenerative disorders, and other chronic 
conditions. The life expectancy of the world population is increasing, and it is estimated that 
by 2025, 29% of the world population will be aged 60 years, and this will lead to an increase 
in the number of older people acquiring age-related chronic diseases. This will place greater 
ﬁ  nancial burden on health services and high social cost for individuals and society. In order 
to acheive healthy aging the older people should be encouraged to acquire healthy life styles 
which should include diets rich in antioxidants. The aim of this review is to highlight the main 
themes from studies on free radicals, antioxidants and co-factors, and to propose an evidence-
based strategy for healthy aging.
Keywords: free radicals, antioxidants, co-factors, age-related diseases, healthy aging 
Introduction
One of the main driving force, which helps to sustain human life, are the biochemical 
reactions which take place within the organelles and cells of the body. The laws of 
nature are such that one moves from infancy, to childhood, then into adulthood, and 
ﬁ  nally one becomes a frail human being eventually leading to death. This aging process 
is a common feature of the life cycle of virtually all multicellular organisms. The 
number of people aged 65 and over is predicted to increase by approximately 53% 
in the United Kingdom by the year 2031 and similar changes are likely to be seen 
in other developed countries due to low birth rates and increasing life expectancy, 
which will lead to an increasingly elderly population (Majeed and Aylin 2005). This 
predicted gain in life expectancy would potentially lead to an increase in the number 
of older people acquiring age-related chronic diseases of the cardiovascular, brain, and 
immune systems. This can cause loss of autonomy, dependence and high social costs 
for individuals and society, and will impose increased workload and ﬁ  nancial pressures 
on healthcare systems worldwide. Due to this there is a major interest in understanding 
of the biochemistry of aging and providing a database of “anti-aging” medicines, diet 
and commercial products which can provide safe, effective and practical methods for 
increasing longevity with a good quality of life during aging, and thus decrease the 
dependence of elderly people on expensive high-tech medicine (Rahman 2003). The 
three main areas of research, which are interlinked and can contribute or delay the 
aging process are; studies involving free radicals, antioxidants, and co-factors. There 
have been a signiﬁ  cant number of studies within these areas and the purpose of this Clinical Interventions in Aging 2007:2(2) 220
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review is to highlight the main themes from these studies 
which can provide a better insight into the mechanisms of 
aging, and thus provide an anti-aging strategy.
Free radicals
Free radicals can be deﬁ  ned as reactive chemical species 
having a single unpaired electron in an outer orbit (Riley 
1994). This unstable conﬁ  guration creates energy which is 
released through reactions with adjacent molecules, such 
as proteins, lipids, carbohydrates, and nucleic acids. The 
majority of free radicals that damage biological systems are 
oxygen-free radicals, and these are more generally known 
as “reactive oxygen species” (ROS). These are the main 
byproducts formed in the cells of aerobic organisms, and can 
initiate autocatalytic reactions so that molecules to which they 
react are themselves converted into free radicals to propagate 
the chain of damage. ROS can be (i) generated during UV 
light irradiation and by X-rays and gamma rays (ii) produced 
during metal catalyzed reactions (iii) are present in the 
atmosphere as pollutants (iv) are produced by neutrophils and 
macrophages during inﬂ  ammation, and (iv) are by-products 
of mitochondrial catalyzed electron transport reactions, and 
various other mechanisms (Cadenas 1989). The amount 
of free radical production is determined by the balance of 
many factors, and ROS are produced both endogenously 
and exogenously. The endogenous sources of ROS include 
mitochondria, cytochrome P450 metabolism, peroxisomes, 
and inﬂ  ammatory cell activation (Inoue et al 2003). Hydrogen 
peroxide, although not a radical species is produced in the 
mitochondria as is its ROS precursor superoxide. It has 
been proposed that ubisemiquinone is the main reductant 
of oxygen in mitochondrial membranes and the generation 
of superoxide within mitochondria is approximately 
2–3 nmol/min per mg of protein, the presence of ubiquitous 
indicates it to be the most important physiological source 
of this radical in living organisms (Inoue et al 2003). Since 
mitochondria are the major site of free radical generation, 
they contain a variety of antioxidants, which are present on 
both sides of their membranes in order to minimize ROS 
induced stress (Cadenas and Davies 2000). There are also 
other cellular sources of superoxide radicals present such as 
the enzyme xanthine oxidase, which catalyzes the reaction of 
hypoxanthine to xanthine and xanthine to uric acid. In both 
steps, molecular oxygen is reduced, forming the superoxide 
anion followed by the generation of hydrogen peroxide 
(Valko et al 2004). 
Additional endogenous sources of cellular ROS are 
neutrophils, esinophils and macrophages. On activation, 
macrophages initiate an increase in oxygen uptake giving 
rise to a variety of ROS, including superoxide anion, nitric 
oxide and hydrogen peroxide (Conner and Grisham 1996). 
Cytochrome P450 has also been proposed as a source of 
ROS since on its induction, superoxide anion and hydrogen 
peroxide production takes place following the breakdown or 
uncoupling of the P450 cycle (Valko et al 2006). In addition, 
microsomes and peroxisomes are sources of ROS, and 
microsomes are responsible for the majority of hydrogen 
peroxide produced in vivo at hyperoxia sites (Gupta et al 
1997). ROS can also be produced by a host of exogenous 
sources such as xenobiotics, chlorinated compounds, envi-
ronmental agents, metals (redox and nonredox), ions, and 
radiation (Valko et al 2006).
The generation of free radicals in cells is closely linked 
with the participation of redox-active metals (Shi et al 2004), 
which in itself is largely linked to an iron (in part to copper) 
redox couple, and is maintained within strict physiological 
limits. The iron under certain circumstances, can partici-
pate in the Fenton reaction, generating the highly reactive 
hydroxyl radical (Leonard et al 2004) which if produced 
in vivo, can react close to its site of formation hence causing 
localized damage. Additional radicals derived from oxygen 
are peroxy radicals, which are high-energy species, and they 
display biological diversity in their actions. These induce 
lipid peroxidation whose measurement is the most frequently 
cited evidence to support the involvement of peroxyl radical 
in human disease and toxicology (Gutteridge 1995; Cadenas 
and Sies 1998). 
It has been established that ROS can be both harm-
ful and beneficial in biological systems depending on 
the environment (Lopaczynski and Zeisel 2001; Glade 
2003). Beneﬁ  cial effects of ROS involve, for example, 
the physiological roles in cellular responses to noxia such 
as defense against infectious agents, and in the function 
of a number of cellular signaling systems. In contrast, at 
high concentrations, ROS can be mediate damage to cell 
structures, including lipids and membranes, proteins and 
nucleic acids; this damage is often referred as “oxidative stress” 
(Poli et al 2004). The harmful effects of ROS are balanced 
by the action of antioxidants, some of which are enzymes 
present in the body (Halliwell 1996). Despite the presence of 
the cell’s antioxidant defense system to counteract oxidative 
damage from ROS, oxidative damage accumulates during 
the life cycle and has been implicated in aging and age-
dependent diseases such as cardiovascular disease, cancer, 
neurodegenerative disorders and other chronic conditions 
(Rahman 2003) (see Figure 1). Clinical Interventions in Aging 2007:2(2) 221
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Free radicals and aging
Aging can generally be deﬁ  ned as a progressive decline in 
the efﬁ  ciency of biochemical and physiological processes 
after the reproduction phase of life. This contribution of 
the aging process to changes occurring with age are small 
early in life but rapidly increase with age because of the 
exponential nature of aging (Figure 1). Many theories 
have been put forward to explain the phenomenon of aging 
(Armbrecht 2001; Biesalski 2002; Finkel and Holbrook 2002; 
Sohal et al 2002; Balaban et al 2005); and all of these have 
their strengths and weaknesses, and it’s likely that they all 
contribute to the mechanisms of aging. Among the theories 
proposed, the “free radical theory of aging” (Harman 1956) 
has gained universal acceptance and is supported by the 
fact that production of free radicals and free radical damage 
increases with age (Sohal and Weindruch 1996). This theory 
postulates that free radicals in the body cause oxidative dam-
age to cellular components, a process which results in altered 
cellular function, compromised tissue and organ function, 
and ultimately death. The body takes molecular oxygen and 
uses it to produce energy via oxidative phosphorylation in 
mitochondria, and this, and other metabolic reactions gener-
ate free radicals imposing oxidative stress on proteins, DNA 
and lipids. The free radial theory is supported by the “rate 
of living” hypothesis, which inversely links metabolic rate 
with the longevity of the organisms (Ku et al 1993) and it 
is also well established that oxidative damage to proteins, 
DNA and lipids increases with age (Sohal and Weindruch 
1996). Evidence to support the free radical theory of aging 
has been mainly obtained in experimental animal models. 
The restriction of caloric intake in rodents has been shown to 
increase lifespan, increase free radical defenses, and reduce 
oxidative damage. The tissues of species which live longer 
are also less susceptible to oxidative damage then tissue of 
species which have shorter life spans and this is supported by 
the fact that conditions which generate increased free radical 
production such as a high metabolic rate are associated with 
a shorter lifespan (Agarwal and Sohal 1996). Although evi-
dence exists to support the free radical theory and the decline 
in physiological function in aging, some questions relating 
to aging are still unresolved. Free radical mediated oxidative 
stress increases with age, and thus may overwhelm the natural 
repair systems in the elderly (Kowald and Kirkwood 2000) 
and is a major contributor to diseases associated with aging 
(Ames et al 1993) an outline of which is given below. 
Cardiovascular disease
The development of atherosclerosis depends on the 
balance between proinﬂ  ammatory; anti-inﬂ  ammatory, and 
antioxidative defense mechanisms (Scott 2004). Vascular 
proliferation and inﬂ  ammation are closely linked (Dzay et al 
2002), and excessive proliferation of vascular cells plays 
an important role in the pathology of vascular occlusive 
disease. Free radicals are considered to play a casual role 
in this process (Schachinger and Zeiher 2002), and ROS 
lead to the oxidation of low density lipoprotein (OxLDL), 
and this accumulates within plaques, and contributes to the 
inﬂ  ammatory state of atherosclerosis and plays a key role in 
its pathogenesis (Galle et al 2006). Oxidized-LDL leads to 
endothelial dysfunction, and can result in either cell growth 
or apoptotic cell death and can cause vasoconstriction.
Free radicals have also been implicated in congestive 
heart failure (CHF), the annual incidence of which is one 
to ﬁ  ve per 1000 person, and the relative incidence doubles 
for each decade of life after the age of 45. Experimental 
evidence suggests a direct link between free radical produc-
tion and CHF (Mariani et al 2005) and the presence of ROS 
in circulating blood is also the key intermediary related to 
vascular injury and organ dysfunction (Fukai et al 2002; 
Elahi and Matata 2006).
Stroke
In Western countries stroke is the main cause of disability and 
mortality among the aging population, and ischemic stroke 
accounts for about 75% of all cases while hemorrhagic stroke 
is responsible for almost 15% of all strokes (Mariani et al 
2005). There is evidence that stroke is associated with free 
radicals arising from sources such as xanthine oxidase, cyclo-
oxygenase, inﬂ  ammatory cells and mitochondria (Piantadosi 
and Zhang 1996), and these can potentially cause neuronal 
death (Alexandrova et al 2004). The mitochondrial electron 
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is also a likely source of free radicals (Simms and Anderson 
2002). This can lead to an increased formation of superoxide 
radical anions as supported by the fact that knockout mice for 
mitochondrial superoxide dismutase (mSOD) genes display 
larger brain lesions after focal ischemia (Murakami et al 
1998). The accumulation of blood borne inﬂ  ammatory cells 
such as neutrophils and monocytes/macrophages, which can 
occur during reperfusion, can also promote further oxidative 
stress. Increased levels of oxidative damage to DNA and 
evidence for lipid peroxidation has also been demonstrated in 
ischemic stroke patients (Mariani et al 2005). In addition, the 
increased levels of ROS can make the brain more susceptible 
to oxidative stress due to a variety of reasons namely: the 
brain consumes a signiﬁ  cant amount of the body oxygen, has 
a relatively poor antioxidant defense system, is enriched in 
pro-oxidant molecules and contains high concentration of 
readily peroxidizable lipids (Cherubini et al 2005a).
Neurodegenerative diseases
Neurodegenerative diseases affect the central nervous system 
and are characterized by loss of speciﬁ  c neuronal populations 
and quite often intraneuronal, as well as extracellular accumu-
lation of ﬁ  brillary materials. Decrements in motor function and 
decrements in memory are two main behavioral parameters 
that are altered in senescence in both humans and animals. 
Primary degenerative brain disease and diseases related to 
cerebral vascular disturbances are the leading cause of dis-
ability in old age and can cause loss of autonomy, dependence, 
and high social costs for individuals and the society. There is 
growing evidence that free radicals are involved in the initia-
tion of cellular injury observed in neurodegenerative diseases 
(Emerit et al 2004) an outline of which are given below:
Alzheimers’s disease (AD)
This is the most common neurodegenerative disorder and is 
characterized by loss of neurons and synapses resulting in 
cognitive impairment and a gradual loss of memory, language 
skills, and reasoning leading to dementia and ﬁ  nally death 
(Selkoe 2004). The onset of AD is gradual, with clinical 
symptoms appearing between 60–70 years of age and is 
characterized by both synaptic loss and nerve cell loss. It is 
associated with aging and several studies show logarithmic 
age-dependent increases in oxidized proteins, lipids and DNA 
in AD patients (Floyd and Hensley 2002); these observed 
increases are not accounted for by the decreased activity of 
the antioxidant protective enzymes. Oxidative damage may 
also play a role in amyloid deposition in AD, and oxidizing 
conditions can cause protein cross-linking and aggregation 
of β-amyloid protein (Dyrks et al 1993), and also contribute 
to aggregation of tau (Troncoso et al 1993), and other 
cytoskeletal proteins (Bellomo and Mirabelli 1992). The 
β-amyloid protein is also reported to cause the oxidation of the 
nonsaturated carbohydrate side chains of membrane lipids, 
which leads to the disintegration of the neural membrane 
thus resulting in cell lysis (Behl et al 1994). Lipid peroxida-
tion has also been quantitatively assessed in AD brains and 
increased brain levels of 4-hydroxy-2-noneanal glutathione 
conjugates have been recently reported (Völkel et al 2006). 
There is also an increase in the DNA damage of lymphocytes 
obtained from AD donors (Mecocci et al 1998) whilst oxida-
tive modiﬁ  cation of proteins in the frontal cortex of AD brain 
has also been reported (Korolainen et al 2006). 
Huntington’s disease (HD)
This is an inherited, autosomal dominant neurodegenerative 
disease, which causes uncontrollable movements and restless-
ness as well as irritability and depression (Margolis and Ross 
2003). Direct evidence for a defect in oxidative phosphoryla-
tion in HD patients is supported by the discovery of a three-
fold increase in lactate concentrations in the occipital cortex 
and in the basal ganglia (Jenkins et al 1993). There is further 
evidence to support the involvement of free radicals in the 
pathogenesis of HD in that increased levels of F2-isoprostanes 
have been detected in the cerebro-spinal ﬂ  uid of HD patients 
compared to the control group (Montine et al 1999).
Parkinson’s disease (PD)
This is a progressive neurodegenerative movement disorder 
and is the most common form of motor system degenera-
tion affecting approximately 1% of the population over the 
age of 65 (Moore et al 2005). Clinical symptoms include 
bradykinesia, rigidity, postural instability, and resting tremor. 
Experimental evidence supports the involvement of free 
radicals in the pathogenesis of PD. It has been observed that 
that oxidation of dopamine yields potentially toxic semiqui-
nones and that the accelerated metabolism of dopamine by 
monoamine-oxidase-B may induce an excessive formation 
of hydrogen peroxide, superoxide anions, and hydroxyl 
radicals. Further evidence of the involvement of free radicals 
comes from the fact that oxidative stress is responsible for 
the initiation of nigral dopamine neuron loss. The substantia 
nigra has a high metabolic rate combined with both a high 
content of oxidizable species, including dopamine and 
dopamine-derived ROS, neuromelanin, polyunsaturated fatty 
acids, iron, and a low content of antioxidants. Thus oxidative 
stress can dominate and result in the production of ROS, Clinical Interventions in Aging 2007:2(2) 223
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which serve both to maintain the oxidative stress level, and 
to initiate/propagate apoptosis of the dopaminergic neurons 
(Wersinger and Sidhu 2002; Hald and Lotharius 2005). PD 
has also been found to be associated with increased oxida-
tive damage to DNA (Migliore et al 2002) proteins (Choi 
et al 2006) and lipids (Agil et al 2006), and further signs of 
oxidative damage in PD patients is supported by the ﬁ  nding 
that elevated levels of the pro-oxidant iron are present in the 
brains of PD patients (Fasano et al 2006). 
Cancer
Carcinogenesis is a complicated, multi-stage process in which 
healthy cells are transformed into abnormal cells as a result 
of a series of mutations and changes in the patterns of gene 
expression. Factors predisposing to malignancy include, inher-
ited traits, environmental agents, diet, and the risk of cancer 
increases with age. Cancer development can be described by 
three stages: initiation, promotion and progression, and ROS 
can act in all these stages of carcinogenesis (Klaunig and 
Kamendulis 2004). It is also well established that free radicals 
are known to react with all components of DNA, thus damaging 
its bases and the deoxyribose backbone (Dizdaroglu et al 2002) 
causing mutations in crucial genes, which ultimately may lead 
to cancer (Ames and Shigenaga 1992).
The permanent modiﬁ  cation of genetic material induced 
by free radicals represents the ﬁ  rst step involved in muta-
genesis, carcinogenesis, and aging. In support of this free 
radical-mediated damage to DNA has been found in various 
cancer tissues, and there is also a direct link between the size 
of benign tumors and the amount of DNA oxidized product, 
8-hydroxyguanine (8-OH-G) adduct formation; indicating that 
the level of 8-OH-G may be important in the transformation 
of benign to malignant tumor (Loft and Poulsen 1996). This 
damage to the DNA can result either in arrest or induction 
of transcription, induction of signal transduction pathways, 
replication errors, and genomic instability, all of which are 
associated with carcinogenesis (Marnett 2000; Cooke et al 
2003). A high level of oxidative stress can induce apoptosis 
or even necrosis; however, a low level of oxidative stress 
can stimulate cell division and thus promote tumor growth 
(Dreher and Junod 1996). ROS probably enhance the ﬁ  nal 
irreversible stage of carcinogenesis, which is characterized 
by accumulation of additional genetic damage, leading to the 
transition of the cell from benign to malignant.
Diabetes
There is increasing evidence that free radical induced damage 
also plays a signiﬁ  cant part in the development of insulin 
resistance, β-cell dysfunction, impaired glucose tolerance, 
and type 2 diabetes mellitus (Jay et al 2006; Wright et al 
2006). Hyperglycemia can induce oxidative stress, which 
increases with age, via several mechanisms including 
glucose auto oxidation, the formation of advanced glycation 
end-products (AGE), and activation of the polyol pathway. 
Other circulating factors that are elevated in diabetics such as 
free fatty acids and leptin also contribute to increased ROS 
(Jay et al 2006). There is a signiﬁ  cant increase in protein 
glycation (AGE) with age (Poggioli et al 2002), which is 
also increased in diabetics (Wautier and Schimdt 2004). 
The accumulation of AGE leads to an increase in the micro 
vascular lesions, which are present in diabetic retinopathy, 
and is also responsible for cardiovascular complications, 
which are seen in diabetic patients (Wautier and Schmidt 
2004; Jay et al 2006). The damage caused by ROS has also 
been implicated in primary open angle glaucoma (POGA), 
which is the leading cause of irreversible blindness and the 
second most common cause of all blindness after cataracts. 
The incidence of POAG is linked to old age, thus advanced 
age represents a major risk factor for this disease (Izzotti 
et al 2006).
The biochemical and physiological damage induced due 
to free radical mediated oxidative stress can be counteracted 
by antioxidants, which are discussed below.
Antioxidants
The term “antioxidant” refers to any molecule capable of sta-
bilizing or deactivating free radicals before they attack cells. 
Humans have evolved highly complex antioxidant systems 
(enzymic and nonenzymic), which work synergistically, 
and in combination with each other to protect the cells and 
organ systems of the body against free radical damage. The 
antioxidants can be endogenous or obtained exogenously eg, 
as a part of a diet or as dietary supplements. Some dietary 
compounds that do not neutralize free radicals, but enhance 
endogenous activity may also be classiﬁ  ed as antioxidants.
An ideal antioxidant should be readily absorbed and 
quench free radicals, and chelate redox metals at physiologi-
cally relevant levels. It should also work in both aqueous 
and/or membrane domains and effect gene expression in a 
positive way. Endogenous antioxidants play a crucial role 
in maintaining optimal cellular functions and thus systemic 
health and well-being. However, under conditions, which 
promote oxidative stress, endogenous antioxidants may not 
be sufﬁ  cient and dietary antioxidants may be required to 
maintain optimal cellular functions. The most efﬁ  cient enzy-
matic antioxidants involve glutathione peroxidase, catalase Clinical Interventions in Aging 2007:2(2) 224
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and superoxide dismutase (Mates et al 1999). Nonenzymatic 
antioxidants include Vitamin E and C, thiol antioxidants 
(glutathione, thioredoxin and lipoic acid), melatonin, 
carotenoids, natural flavonoids, and other compounds 
(McCall and Frei 1999). Some antioxidants can interact with 
other antioxidants regenerating their original properties; this 
mechanism is often referred to as the “antioxidant network” 
(Sies et al 2005). There is growing evidence to support a 
link between increased levels of ROS and disturbed activi-




There are two forms of this enzyme, one which is selenium-
dependent (GPx, EC1.11.1.19) and the other, which is 
selenium-independent (glutathione-S-transferase, GST, 
EC2.5.1.18) (Mates et al 1999). The differences are due to the 
number of subunits, catalytic mechanism, and the bonding of 
selenium at the active centre, and glutathione metabolism is 
one of the most important antioxidative defense mechanisms 
present in the cells. There are four different Se-dependent 
glutathione peroxidases present in humans (Chaudière and 
Ferrari-Iliou 1999), and these are known to add two electrons 
to reduce peroxides by forming selenoles (Se-OH) and the 
antioxidant properties of these seleno-enzymes allow them 
to eliminate peroxides as potential substrates for the Fenton 
reaction. Selenium-dependent glutathione peroxidase acts 
in association with tripeptide glutathione (GSH), which 
is present in high concentrations in cells and catalyzes the 
conversion of hydrogen peroxide or organic peroxide to 
water or alcohol while simultaneously oxidizing GSH. It also 
competes with catalase for hydrogen peroxide as a substrate 
and is the major source of protection against low levels of 
oxidative stress (Chaudière and Ferrari-Iliou 1999).
Catalase (EC1.11.1.6)
This enzyme is present in the peroxisome of aerobic 
cells and is very efﬁ  cient in promoting the conversion of 
hydrogen peroxide to water and molecular oxygen. Catalase 
has one of the highest turnover rates for all enzymes: one 
molecule of catalase can convert approximately 6 million 
molecules of hydrogen peroxide to water and oxygen each 
minute (Mates et al 1999).
Superoxide dismutase (SOD), (EC 1.15.1.1)
This is one of the most effective intracellular enzymatic 
antioxidants and it catalyzes the conversion of superoxide 
anions to dioxygen and hydrogen peroxide. Superoxide 
dismutase exists in several isoforms, which differ in the 
nature of active metal centre, amino acid composition, 
co-factors and other features. There are three forms of SOD 
present in humans: cytosolic Cu, Zn-SOD, mitochondrial 
Mn-SOD, and extra cellular-SOD (Landis and Tower 2005). 
Superoxide dismutase neutralizes superoxide ions by going 
through successive oxidative and reductive cycles of transi-
tion metal ions at its active site (Chaudière and Ferrari-Iliou 
1999). Cu, Zn-SOD has two identical subunits with a 
molecular weight of 32 kDa (Mates et al 1999) and each of the 
subunit contains as the active site, a dinulcear metal cluster 
constituted by copper and zinc ions, and it speciﬁ  cally cata-
lyzes the dismutation of the superoxide anion to oxygen and 
water. The mitochondrial Mn-SOD is a homotetramer with a 
molecular weight of 96 kDa and contains one manganese atom 
per subunit (Mates et al 1999), and it cycles from Mn(III) to 
Mn(II), and back to Mn(III) during the two-step dismutation 
of superoxide. Extra cellular superoxide dismutase contains 
copper and zinc, and is a tetrameric secretary glycoprotein 
having a high afﬁ  nity for certain glycosaminoglycans such 
as heparin and heparin sulphate (Mates et al 1999), however, 
its regulation in mammalian tissues occurs primarily in a 




This is a fat-soluble vitamin existing in eight different forms. 
In humans, α-tocopherol is the most active form, and is the 
major powerful membrane bound antioxidant employed by 
the cell (Hensley et al 2004). The main function of Vitamin E 
is to protect against lipid peroxidation (Pryor 2000), and there 
is also evidence to suggest that α-tocopherol and ascorbic 
acid function together in a cyclic-type of process. During 
the antioxidant reaction, α-tocopherol is converted to an 
α-tocopherol radical by the donation of a labile hydrogen to 
a lipid or lipid peroxyl radical, and the α-tocopherol radical 
can therefore be reduced to the original α-tocopherol form 
by ascorbic acid (Kojo 2004).
Vitamin C (ascorbic acid)
This is an important and powerful water-soluble antioxidant 
and thus works in aqueous environments of the body. 
Its primary antioxidant partners are Vitamin E and the 
carotenoids as well as working along with the antioxidant 
enzymes. Vitamin C cooperates with Vitamin E to regenerate 
α-tocopherol from α-tocopherol radicals in membranes and Clinical Interventions in Aging 2007:2(2) 225
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lipoproteins (Carr and Frei 1999; Kojo 2004), and also raises 
intracellular glutathione levels thus playing an important role 
in protein thiol group protection against oxidation (Naziroglu 
and Butterworth 2005). 
Thiol antioxidants
The major thiol antioxidant is the tripeptide glutathione 
(GSH), which is a multifunctional intracellular antioxidant 
and is considered to be the major thiol-disulphide redox buf-
fer of the cell (Masella et al 2005). It is abundant in cytosol, 
nuclei, and mitochondria, and is the major soluble antioxidant 
in these cell compartments (Masella et al 2005). Glutathione 
has also been shown to play a role in cell senescence since 
studies involving human ﬁ  broblasts have shown that the 
intracellular glutathione level has a strong inﬂ  uence on the 
induction of a post-mitotic phenotype, and that by implication 
depletion of glutathione may play a signiﬁ  cant role in the 
cellular aging in human skin (Alaluf et al 2000). The reduced 
form of glutathione is GSH, glutathione, whilst the oxidized 
form is GSSG, glutathione disulphide. The antioxidant capac-
ity of thiol compounds is due to the sulphur atom, which can 
easily accommodate the loss of a single electron (Karoui et al 
1996). Oxidized glutathione (GSSG) is accumulated inside 
the cells and the ratio of GSH/GSSG is a good measure of 
oxidative stress of an organism (Dröge 2002). The main 
protective roles of glutathione against oxidative stress are 
that it can act as a co-factor for several detoxifying enzymes, 
participate in amino acid transport across plasma membrane, 
scavenge hydroxyl radical and singlet oxygen directly, and 
regenerate Vitamins C and E back to their active forms 
(Masella et al 2005).
Another thiol antioxidant is the thioredoxin (TRX) 
system; these are proteins with oxidoreductase activity and 
are ubiquitous in both mammalian and prokaryotic cells 
(Holmgren 1985). It also contains a disulphide and pos-
sesses two redox-active cysteins within a conserved active 
site (Cys-Gly-Pro-Cys) (Nakamura et al 1997). Thioredoxin 
contains two adjacent –SH groups in its reduced form that 
are converted to a disulphide unit in oxidized TRX when it 
undergoes redox reactions with multiple proteins.
Thioredoxin levels are much less than GSH, however, 
TRX and GSH may have overlapping as well as compart-
mentalized functions in the activation and regulation of 
transcription factors (Valko et al 2006).
The third important thiol antioxidant is the natural com-
pound α-Lipoic acid (ALA), which is a disulphide derivative 
of octanoic acid and is sometimes referred to as thiothic 
acid. It is both water and fat-soluble, and therefore, is widely 
distributed in both cellular membranes and the cytosol of 
eukaryotic and prokaryotic cells. α-Lipoic acid is readily 
absorbed from the diet and is converted rapidly to its reduced 
form, dihydrolipoic acid (DHLA) (Smith et al 2004). Both 
ALA and DHLA are powerful antioxidants and they exert 
their effects by scavenging free radicals, metal ion chelation 
and antioxidant recycling, and repairing protein damage 
due to oxidative stress either in the cytosol or hydrophobic 
domains (Navari-Izzo et al 2002).  Dihydrolipoic acid is a 
stronger antioxidant than lipoic acid and can act synergisti-
cally with other antioxidants such as glutathione, ascorbate 
and tocopherol. However, it can also exert pro-oxidant prop-
erties both by its iron-reducing ability and by its ability to 
generate sulfur-containing radicals that can damage proteins 
(Navari-Izzo et al 2002). 
Melatonin (N-acetyl-5-methoxytryptamine)
This is an indoleamine neurohormone that is synthesized 
mainly in the pineal gland and has many effects on a wide 
range of physiopathological functions. One major function of 
melatonin is to scavenge free radicals in oxygen metabolism, 
thereby potentially protecting against free radical-induced 
damage to DNA, proteins and membranes, thus it has the 
potential to play an important role in the reduction of free 
radical mediated diseases (Rahimi et al 2005).
Carotenoids
These are mainly colored pigments present in plants and 
microorganisms and epidemiological studies have revealed 
that an increased consumption of a diet rich in carotenoids 
is correlated with a lower risk of age-related diseases. Carot-
enoids contain conjugated double bonds and their antioxidant 
activity arises due to the ability of these to delocalize unpaired 
electrons (Mortensen et al 2001). This is also responsible 
for the ability of carotenoids to physically quench singlet 
oxygen without degradation and for the chemical reactivity 
of carotenoids with free radicals. The efﬁ  cacy of carotenoids 
for physical quenching is related to the number of conjugated 
double bonds present in the molecule, which determines their 
lowest triplet energy level. They can also scavenge peroxy 
radical thus preventing damage in lipophilic compartments 
(Stahl and Sies 2003), however, the carotenoid β-carotene can 
also act as a pro-oxidant causing an increase in lipid peroxida-
tion (Polozza et al 2003). The concentrations of carotenoids 
and the partial pressure of oxygen are also important factors 
in their effectiveness as antioxidants. Carotenoids, in particu-
lar β-carotene exhibit antioxidant properties at low oxygen 
partial pressure but become pro-oxidants at high pressures Clinical Interventions in Aging 2007:2(2) 226
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of oxygen and similarly, at high carotenoid concentrations, 
pro-oxidant behavior is displayed (Rice-Evans et al 1997; 
Stahl and Sies 2003). 
Flavonoids
These are a broad class of low molecular ubiquitous groups 
of plant metabolites and are an integral part of the human 
diet (Rice-Evans 2001). Flavonoids are benzo-γ-pyrone 
derivatives consisting of phenolic and pyrane rings and 
during metabolism hydroxyl groups are added, methylated, 
sulfated or glucuronidated.
There is intense interest in ﬂ  avonoids due to their anti-
oxidant and chelating properties and their possible role in 
the prevention of chronic and age-related diseases (Schroeter 
et al 2002). 
Flavonoids are present in food mainly as glycosides and 
polymers (Hammerstone et al 2000) and these comprise a 
substantial fraction of dietary ﬂ  avonoids (Santos-Buelga and 
Scalbert 2000). The biological properties of ﬂ  avonoids are 
determined by the extent, nature, and position of the sub-
stituents and the number of hydroxyl groups (Schroeter et al 
2002). These factors also determine whether a ﬂ  avonoid will 
act as an antioxidant or as a modulator of enzyme activity, or 
whether it possesses antimutagenic or cytotoxic properties. 
The most reported activity of ﬂ  avonoids is their protection 
against oxidative stress (Rice-Evans 2001). Thus ﬂ  avonoids 
can scavenge peroxyl radicals, and are effective inhibitors 
of lipid peroxidation, and can chelate redox-active metals, 
and thus prevent catalytic breakdown of hydrogen peroxide 
(Fenton chemistry). However, under certain conditions, 
ﬂ  avonoids can also display pro-oxidant activity and this is 
thought to be directly proportional to the total number of 
hydroxyl groups (Cao et al 1997), and they have also been 
reported to modulate cell signaling (Schroeter et al 2002).
Antioxidants and age-related 
diseases
The human body has a host of mechanisms such as the DNA-
repair systems to deal with free radical induced damage and 
depending on the circumstances, environmental and genetic 
factors can either increase or decrease the incidence of dis-
eases associated with old age (Figure 2). Epidemiological 
studies have demonstrated that diet plays a crucial role in 
the prevention of age-related chronic diseases especially if 
combined with regular physical activity and abstaining from 
smoking (Willett 2006). Free radicals and oxidative stress are 
recognized as important factors in the biology of aging and 
of many age-related diseases. One mechanism to slow down 
the aging process and the decline in the vital body functions 
is to modulate oxidative stress by calorie restriction, how-
ever, this is difﬁ  cult to achieve. Hence, dietary components 
with antioxidant activity have received particular attention 
because of their potential role in modulating oxidative stress 
associated with aging and chronic conditions. Several studies 
have indicated potential roles for dietary antioxidants in the 
reduction of age-related diseases (Meydani et al 2001). This 
is supported by the fact that in elderly subjects a higher daily 
intake of fruits and vegetables is associated with an improved 
antioxidant status compared to subjects consuming diets poor 
in fruits and vegetables (Anlasik et al 2005). Therefore, the 
use of antioxidants by this group may lower the prevalence 
of diseases associated with old age; evidence supporting this 
is outlined below.
Mediterranean diet, which is rich in fruits and vegetables, 
has been shown to reduce the incidence of cardiovascular 
disease (Serra-Majem et al 2006; Willett 2006). Evidence is 
now emerging that some dietary antioxidants besides display-
ing traditional antioxidant potential can inﬂ  uence signaling 
pathways and gene expression relevant in atherosclerosis 
by mechanisms other than antioxidative ones. Vitamin C 
has been shown to inhibit LDL oxidation in vitro (Alul 
et al 2003) primarily by scavenging free radicals and other 
ROS, thereby preventing them from interacting with LDL. 
The observational data in humans suggest that vitamin C 
ingestion is associated with reduced cardiovascular disease, 
however, the results of randomized controlled trials have 
been mainly disappointing (Cherubini et al 2005b). A ran-
domized double-blind crossover trial has shown a positive 
correlation of plasma Vitamin C with resistance to LDL to 
oxidation (Samman et al 2003), however, in contrast to this, 
in another recent study no correlation between Vitamin C and 
LDL resistance to oxidation has also been reported (Kaliora 
et al 2006). Vitamin E has also been shown to inhibit LDL 






















Figure 2 Summary of mechanisms involved in the prevention of diseases 
associated with old age.
Notes: (–) Reduction of diseases; (+) Induction of diseases. There is interaction 
between body’s antioxidant defense system, dietary antioxidants, and co-factors in 
the reduction of diseases associated with old age.Clinical Interventions in Aging 2007:2(2) 227
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Townsend 2005), and also increases LDL oxidative resistance 
(Dieber-Rotheneder et al 1991; Heitzer et al 1999, Palomaki 
et al 1999; Hodis et al 2002), decreases agonist-induced plate-
let aggregation (Munteanu et al 2004), and preserves agonist-
induced vasodilation (Keaney et al 1993; Munteanu et al 
2004) ex vivo. Long term supplementation with Vitamin E 
in hypercholesterolemic patients and/or chronic smokers has 
shown to increase levels of autoantibodies against oxidized 
LDL (Heitzer et al 1999) and it has recently been shown to 
prevent ischemic heart disease (Chattopadhay and Bandyo-
padhyay 2006) however, evidence from other clinical trials is 
controversial and confusing (Kaliora et al 2006) since some 
studies have failed to show a link between dietary supple-
mentation of ∝-tocopherol and LDL resistance to oxidation. 
This may be due to the fact that vitamin E not only acts as an 
antioxidant but can also interact with enzymes and modulate 
genes involved in atherosclerosis (Munteanu et al 2004).
A protective role ﬂ  avonoids in the diet of humans has 
been indicated in some large prospective studies. In vitro 
inhibition of LDL oxidation by ﬂ  avonoids has also been 
demonstrated (Andrikopoulos et al 2002; Vitseva et al 
2005) whilst total antioxidant capacity is increased and 
LDL oxidizability is reduced after consumption of several 
natural products that are rich in ﬂ  avonoids (Rahman 2003; 
Ruel et al 2005). A high ﬂ  avonoid intake is also associated 
with a lower mortality rate from coronary heart disease 
and lower incidence of myocardial infarction in older men 
(Hertog et al 1993), and a reduced risk of coronary heart 
disease in post-menopausal women has been observed 
(Yochum et al 1999). The Zutphen Elderly study also 
demonstrated an inverse relationship between consumption 
of catechin, a predominant ﬂ  avonoid in tea and ischemic 
heart disease mortality in a cohort of 806 men ( Arts et al 
2001). In support of this, black tea consumption has shown a 
decrease in markers of oxidative stress and inﬂ  ammation in 
patients with coronary artery disease (Widlansky et al 2005). 
Carotenoids have shown to increase LDL oxidative resistance 
in ex vivo studies (Levy et al 2000; Upritchard et al 2000), 
however, in another study involving elderly healthy subjects 
supplementation with a carotene mixture or lycopene had 
no effect on oxidative modiﬁ  cation of LDL in vitro, despite 
signiﬁ  cant increase in plasma and LDL concentrations of 
lycopene, α-carotene and β-carotene (Carroll et al 2000). 
In contrast, in another clinical trial a signiﬁ  cant decrease in 
serum LDL cholesterol was observed which was in paral-
lel with an increase in serum lycopene (Agarwal and Rao 
1998). In addition, in patients with diabetes mellitus increased 
susceptibility to LDL oxidation was normalized by natural 
β-carotene or lycopene dietary supplements (Levy et al 2000; 
Omoni and Aluko 2005).
The effect of antioxidants has also been investigated 
on the vascular endothelium since it plays a key role in the 
regulation of vascular tone and its dysfunction correlates with 
cardiovascular disease. Garlic, which is high in antioxidants, 
inhibits the ability of platelets to aggregate, increases anti-
oxidants levels and also inhibits LDL oxidation (Rahman 
2003). It also increases intracellular glutathione (GSH) 
levels in vascular endothelial cells by modulation of the 
GSH redox cycle speciﬁ  cally increasing glutathione disulﬁ  de 
(GSSG) reductase activity and superoxide dismutase (SOD) 
activity (Geng and Lau 1997). The role of antioxidants in 
preventing platelet aggregation is still a matter of contro-
versy and contradictory results have been obtained with the 
antioxidant Vitamins C and E (Kaliora et al 2006). Although, 
the intake of dietary ﬂ  avonids is inversely correlated with 
the risk of mortality from coronary artery disease (Gelijnse 
et al 1999; Omoni and Aluko 2005) its role in platelet func-
tion has provided contrasting evidence. For example, cocoa 
supplementation in healthy subjects signiﬁ  cantly increased 
ﬂ  avonoids levels and decreased platelet aggregation (Murphy 
et al 2003), in support of this in another study chocolate 
consumption also decreased platelet aggregation (Innes 
et al 2003). In contrast, some studies have shown no effect 
of ﬂ  avonoids on platelet aggregation despite an increase in 
its plasma concentration (Gooderham et al 1996; Conquer 
et al 1998). There is currently little data on the effectiveness 
of carotenoids on platelet function. 
Vitamin C supplementation in healthy humans has shown 
recently that its intake results in signiﬁ  cant reduction of 
oxidative stress and inﬂ  ammation as shown by a reduction 
in the concentration of F2-isoprostanes, prostaglandin E2, 
and monocyte chemotactic protein-1 (Sánchez-Moreno et al 
2006). The relationship between antioxidants and gene expres-
sion has also been investigated and evidence is emerging that 
antioxidants may prevent cardiovascular disease inﬂ  uencing 
gene expression directly or via gene promoters, via control 
of regulatory signals, and via post-transcriptional pathways 
(Kaliora et al 2006). The role of phytochemicals in the inhi-
bition of cancer and inﬂ  ammation has also been extensively 
studied and it is now clear that these exert their action by 
modulating phase I and phase II enzymes and by modulating 
the cell signaling pathways involved in inﬂ  ammation (Issa 
et al 2006). In future the role of proteomics and nutrigenomics 
will be important in determining the diet-gene relationship.
Since free radicals are implicated in the pathogenesis of 
neurodegenerative diseases (Emerit et al 2004), the role of Clinical Interventions in Aging 2007:2(2) 228
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antioxidants in their prevention has been gaining popularity. 
It has been reported that the concentration of antioxidant 
varies within the different regions of the brain and some 
enzymatic antioxidants such as catalase are found in lower 
concentrations in the brain when compared to other tissues 
(Gilgun-Sherki et al 2001). A variety of antioxidants have 
been investigated for the reduction of oxidative stress 
associated with AD. It has also been reported that the 
concentrations of Vitamins A, C, E and β-carotene in plasma, 
serum or cerebrospinal ﬂ  uid are lower in AD patients than 
in controls (Schippling et al 2000; Bourdel-Marchasson et al 
2001) and supplementation with these vitamins is useful in 
the prevention of AD (Frank and Gupta 2005). Vitamin E 
is also reported to slow the rate of motor dysfunction in HD 
(Peyser et al 1995; Butterﬁ  eld et al 2002). In contrast, no 
effects of these antioxidants on AD have also been reported 
(Luchsinger et al 2003). It has been suggested that ﬂ  avonoids 
may have neuroprotective effects both in vitro and in vivo 
possibly by their abilities to scavenge ROS (Sutherland 
et al 2006). This is supported by the fact that polyphenols 
found in blueberry have been shown to reverse age-related 
declines in neuronal signal transduction as well as cognitive 
and motor deﬁ  cits and increase hippocampal plasticity (Lau 
et al 2005). In addition, Concord grape juice reverses the 
course of neuronal and behavioral aging possibly through 
a multiplicity of direct and indirect effects that can affect 
a variety of neuronal parameters (Shukitt-Hale et al 2006) 
and curcumin, a powerful antioxidant from the curry spice 
turmeric reduces oxidative damage and amyloid pathology 
associated with AD (Calabrese et al 2003). Garlic, a strong 
antioxidant is also reported to protect against age-related 
maculopathy and cataract formation in the elderly (Cumming 
et al 2000). The role of garlic in preventing cerebral aging 
and dementia is also supported by other studies which indi-
cate that phytochemicals displaying antioxidant properties 
can improve neurological dysfunctions (Youdim and Joseph 
2001; Deschamps et al 2001).
Ginkgo extract has also been investigated in the pre-
vention of neurodegenerative diseases and has a beneﬁ  cial 
effect in the treatment of AD patients (Oken et al 1998; 
Frank and Gupta 2005). In contrast no efﬁ  cacy of Gingko 
extract on AD subjects has also been noted (Van Dongen 
et al 2000; Schneider et al 2005). Hence, larger studies are 
needed to clarify the therapeutics effects of Gingko extract 
in AD subjects.
Melatonin is a potent free radical scavenger and its levels 
decline with age and patients with neurodegenerative diseases 
have signiﬁ  cant reductions of this substance (Liu et al 1999; 
Hardeland et al 2006). It also displays neuroprotective and 
antioxidant properties against amyloid β-protein mediated 
oxidative damage (Frank and Gupta 2005; Hardeland et al 
2006), and displays immunomodulatory properties, and thus 
can play a role in healthy aging (Karasek 2004).
An early biochemical change in PD patients is a reduc-
tion in total glutathione levels (Bharath and Anderson 2005). 
Infusion of GSH in PD patients has been demonstrated to 
improve the symptoms but the therapeutic effects only lasted 
between 2–4 months after GSH treatment was stopped (Sechi 
et al 1996). However, the role of induction of endogenous 
antioxidants in the prevention of neurodegenerative diseases 
needs further investigation. 
Free radicals can induce DNA damage, which can 
lead to mutations in crucial genes thus ultimately leading 
to cancer (Ames and Shigenaga 1992). There is evidence 
to indicate that ROS are involved in cancer initiation and 
promotion and malondialdehyde (MDA) concentration 
is increased in patients with neoplasms (Yeh et al 2005). 
Consumption of potent dietary antioxidants can lower the 
effects of oxidative DNA damage in the aged besides lower-
ing the overall risk of cancer (Block 1991; Donaldson 2004; 
Serra-Majem et al 2006). A recent study has indicated that 
a combination of antioxidants is a powerful adjunctive pre-
ventive treatment for cancer (Eli and Fasciano 2006) since 
the total activity of antioxidant enzymes such as superoxide 
dismutase (SOD) and catalase is reduced in certain types 
of cancers (Oberley 1998; Mates et al 1999). However, the 
invasive potential of cancer cells is also increased in the 
presence of abnormally high levels of Mn-SOD (Valko 
et al 2006). The antioxidant vitamins C and E also have the 
potential to reduce certain types of cancers. Many studies 
have shown that vitamin C protects against cell death trig-
gered by various stimuli and this protection is associated 
with its antioxidant property. Vitamin C supplementation 
studies have shown a reduction in markers of oxidative 
DNA, lipid and protein damage, and in support, vitamin C 
has been shown to regulate factors that can inﬂ  uence gene 
expression, apoptosis, and other cellular functions (You 
et al 200). Intervention with vitamin E supplementation 
has shown a reduction in the risk of colorectal adenomas 
and prostate cancer (Borek 2005; Tucker and Townsend 
2005). However, controversy surrounds the effectiveness 
of vitamins in reducing cancer and negative effects of 
vitamin C and E have also been reported. A study by Miller 
and colleagues (2005) has revealed that vitamin E at doses 
of 400IU or more can actually increase the risk of death, 
however, no risk was reported when vitamin E was used Clinical Interventions in Aging 2007:2(2) 229
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at 200IU or less. There is also an association between 
cancer incidence and various disorders of GSH-related 
enzyme functions especially the alterations of glutathione 
S-transferases (GSTs) (Valko et al 2006). 
Carotenoids also display antiproliferative properties 
when tested in various cancer cell lines. Increased intake 
of lycopene has been reported to attenuate alcohol-induced 
apoptosis in 2E1 cells, and reduces the risk of prostate, lung 
and digestive cancers. This cancer preventative property of 
lycopene is associated with its antioxidant property and its 
ability to induce and stimulate intercellular communication 
via gap junctions which are known to play a role in the regu-
lation of cell growth, differentiation, and apoptosis (Tapiero 
et al 2004). In this context the redox state of the cell is also 
important, as there is evidence to show that redox balance is 
impaired in cancer cells compared with normal cells, which 
may be related to oncogenic stimulation. Antioxidants may 
prevent cancer by inducing phase II detoxifying enzymes 
and activating transcription factors and endogenous antioxi-
dant enzymes such as glutathione peroxidase and catalase 
(Frei and Higdon 2003). It is known that altered levels of 
antioxidant enzymes and nonenzymatic antioxidants as 
well as changes in the related signal pathways are evident 
in many human cancers (McEligot et al 2005). Evidence 
is also emerging that ﬂ  avonoids such as garlic, green tea, 
silibinin, and curcumin have cancer preventive properties 
(Rahman 2003; Mandel et al 2005). In support of this garlic 
is known to enhance scavenging systems in the cells such 
as glutathione, SOD, catalase, and glutathione peroxidase 
(Wei and Lau 1998). Many of these dietary compounds 
appear to act on multiple target signaling pathways which 
include down-regulation of cyclooxygenase-2 (COX-2) and 
down- regulation of the transcription activators, AP-1 and 
NF-κB known to be extremely important in tumor promoter-
induced cell transformation and tumor promotion, and both 
are inﬂ  uenced differentially by the MAPK pathways (Huang 
et al 2002; Sarkar and Li 2004). Further support for the role 
of ﬂ  avonoids in preventing cancer has come from grape 
seed proanthocyanidins which have been reported to inhibit 
UV-radiation-induced oxidative stress and activation of 
MAPK and NF-κB signaling in human epidermal keratino-
cytes (Mantena and Katiyar 2006). Dietary Antioxidants may 
also prevent cancer by potentially suppressing angiogenesis 
by inhibiting interleukin-8 production and the cell junction 
molecule VE-cadherin (Meydani 2001). These studies con-
cur with the epidemiologic, clinical and animal studies that 
consumption of antioxidants is associated with a reduced 
risk of cancer among the elderly.
Oxidative stress is increased with aging and is a contributing 
factor for the initiation and progression of complications in 
diabetes mellitus such as lens cataracts, nephropathy and 
neuropathy (Atli et al 2004, Osawa and Kato et al 2005). The 
use of antioxidants in preventing and treating diabetes has been 
investigated over the last decade. Dietary supplementation 
with a combination of antioxidants, and vitamins C and E has 
reported a reduction in oxidative stress markers in patients 
with type 2 diabetes (Farvid et al 2004; Neri et al 2005). In 
contrast, clinical trials involving Vitamin E supplementation 
on diabetic complications have shown conflicting data 
(Ble-Castillo et al 2005; Guerrero-Romero and Rodríguez-
Morán 2005), however, Vitamin E has a greater effect in 
protecting LDL oxidation in type 2 diabetics who are at a 
greater risk of cardiovascular disease (Anderson et al 1999). 
Similarly, conﬂ  icting data has also been obtained with vitamin 
C supplementation such that decreased fasting plasma insulin 
levels and improved insulin action (Penckofer et al 2002) has 
been reported, whilst another study has reported no effect 
(Darko et al 2002). Further conﬂ  icting data has been observed 
in diabetic postmenopausal women who display a higher level 
of oxidative stress (Varma et al 2005) and supplementation 
with high Vitamin C in this group has been reported to have 
an increased risk of mortality from cardiovascular disease 
(Lee et al 2004). 
Flavonoids also have a role to play in the treatment of 
diabetes (Rahman 2003; Rahimi et al 2005) as these have 
shown to protect against hyperglycemic and alloxan-induced 
oxidative stress in experimental animal models (Hedge et al 
2005). In support, in clinical trials ﬂ  avonoids have shown 
to offer protection against type 2 diabetes in a large cohort 
of women (Song et al 2005). Melatonin has been shown to 
reduce diabetic nephropathy and neuropathy in experimental 
animal models (Baydas et al 2003; Cam et al 2003) but more 
work is required to assess its efﬁ  cacy in humans. 
Finally, there is evidence to support the use of lipoic acid 
in treating type 2 diabetes as lipoic acid displays strong 
antioxidant properties and increases glucose uptake 
through recruitment of the glucose transporter-4 to plasma 
membranes, a mechanism that is shared with insulin-
stimulated glucose uptake (Packer et al 2001). Lipoic acid is 
also reported to improve neural blood ﬂ  ow, endoneural glucose 
uptake, and metabolism and nerve conduction (Ruhnau 
et al 1999; Smith et al 2004). It probably exerts its effect in 
diabetic patients by reducing lipid accumulation in adipose 
and nonadipose tissue (Song et al 2004), by increasing 
glucose uptake and by activating pyruvate dehydrogenase 
complex, which is known to play a major role in the oxidation Clinical Interventions in Aging 2007:2(2) 230
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of glucose-derived pyruvate (Korotchkina et al 2004). It’s 
clear that more human clinical trials are required in order 
to establish the role of antioxidants in the prevention and 
treatment of diabetes.
Antioxidants may also have a role to play in the treat-
ment of symptoms and pathological processes associated 
with menopause (Miquel et al 2006) especially in women 
who suffer high levels of oxidative stress, do not consume 
a healthy diet and are seeking alternative treatments for the 
symptoms of menopause. 
Co-factors
The biochemical deﬁ  nition of a co-factor is that it is an ion 
or a molecule that binds to the catalytic site of an apoenzyme 
rendering it active. Many enzymes have a requirement for metal 
ions for their activity and these metal ions are also referred to 
as co-factors. The major antioxidant enzymes possess transition 
metals or selenium at the catalytic site and the availability of 
cofactors can determine the activity of such enzymes. Some of 
the co-factors involved in the oxidant/antioxidant mechanisms 
have already been outlined, the rest are discussed below.
Different essential metals play an important role in 
controlling oxidative reactions in biological tissues. For 
example copper (Cu) is an essential cofactor in a number of 
critical enzymes including cytochrome C oxidase and copper, 
zinc-superoxide dismutase (Cu, ZN-SOD) (Arredondo and 
Núñez 2005). Although unregulated Cu is also a well known 
pro-oxidant it can through the action of transporter proteins 
such as metallothineins and ceruplasmin exert its antioxida-
tive effects (Leung 1998). A Cu deﬁ  ciency-induced decrease 
in the activity of CuZn-SOD in humans and animals has 
been reported (Turnlund et al 1997; Uriu-Adams et al 2005). 
Copper deﬁ  ciency also decreases the activity of ceruloplasmin, 
which requires Cu for its ferroxidase function (Hellman and 
Gitilin 2002), and it can also lead to a reduction in enzymes 
of the oxidant defense system such as selenium-dependent 
glutathione peroxidase (Se-GPX) and catalase (Chen et al 
1994). Further more a deﬁ  ciency in Cu can also alter other 
ROS scavengers including metallothionein (a Cu and Zn 
containing protein) (Tapia et al 2004) and the nonprotein thiol, 
glutathione (Uriu-Adams and Keen 2005). Copper and zinc are 
also essential co-factors for enzymes involved in the synthesis 
of various bone matrix constituents and could be important in 
the elderly since they may play an important role in reducing 
bone loss in osteoporosis (Lowe et al 2002).
Iron (Fe) is an essential constituent of catalase enzymes, 
hemoglobin and myoglobin, but is also a prooxidant (via Fenton 
reactions) when it is present in excess (Gutteridge 1995; 
Leung 1998; Puntarulo 2005). In the presence of lipids iron 
creates oxidative stress and it has been suggested that subjects 
with high levels of lipids and serum iron are at an increased 
risk of cancer (Mainous et al 2005). Thus, iron chelators such 
as albumin, haptoglobin, lactoferrin, transferring and urate 
also have an important role to play in preventing oxidative 
stress-related diseases (Gutteridge 1995). 
Selenium (Se) is another important co-factor and epide-
miological ﬁ  ndings have linked a lowered Se status to neu-
rodegenerative and cardiovascular diseases as well as to an 
increased risk of cancer (Brenneisen et al 2005). There is 
an association between Se reduction and DNA damage, and 
oxidative stress, and some evidence that Se may affect not 
only cancer risk but also progression and metastasis (Rayman 
2005). Selenium intervention in subjects with a lower Se 
status has shown some beneﬁ  ts in reducing the incidence 
and mortality in all cancers but more speciﬁ  cally in liver, 
prostate, colo-rectal and lung cancers. Its protective effects 
appear to be associated with its presence in the multiform of 
glutathione peroxidases, which are known to protect DNA 
and other cellular damage from oxidative stress (Schrauzer 
2000; Trueba et al 2004). 
The element manganese (Mn) is another co-factor 
involved in antioxidant defense mechanisms and is a vital 
component of Mn-SOD enzyme, which plays a crucial role 
in protecting mitochondria from free radical attack (Leung 
1998). Zinc (Zn) another component of SOD is also involved 
in antioxidant defense systems and protects the vascular and 
immunological systems from the damaging affects of free 
radical species (Kuppusamy et al 2005), and it is also a key 
constituent or co-factor of over 300 mammalian proteins 
which may have a role in the prevention of initiation and 
progression of cancer. Evidence supports the fact that Zn 
deﬁ  ciency can impair the host protective mechanisms 
designed to protect against DNA damage, thus increasing 
the risk of cancer (Ho 2004), and it also plays an important 
role as an antioxidant and/or as a co-factor in keeping the 
skin healthy (Rostan et al 2002), thus it can play an important 
role in healthy aging.
Coenzyme Q10 (Co Q10) (Ubiquinone) is fat-soluble 
quinine that transfers electrons from complexes I and II 
to complex III within the mitochondria, this process being 
coupled to ATP production. In its reduced form, Co Q10 also 
inhibits lipid peroxidation and can protect mitochondrial 
inner-membrane proteins and DNA from oxidative damage, 
and is the most widely used co-factor supplement in the treat-
ment of mitochondrial disorders (Turunen et al 2004). CoQ is 
commonly used for treatment of cardiomyopathy, (Langsjoen Clinical Interventions in Aging 2007:2(2) 231
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and Langsjoen 1999) and neurological disorders such as 
Parkinson’s disease and diabetes, and can thus prevent age-
related mitochondrial dysfunction (Littarru and Tiano 2005). 
Most promising results have been obtained in the treatment 
of neurological disorders whilst its use in the treatment of 
cardiovascular disease and diabetes has produced contradic-
tory data (Bonakdar and Guarneri 2005). 
Riboﬂ  avin (Vitamin B2) is another co-factor, which is 
converted to ﬂ  avin dinucleotide, which serves as a coenzyme 
for glutathione reductase and other enzymes (Manthey 
et al 2006). Low intakes of Riboﬂ  avin have been associated 
with different diseases including cancer and cardiovascular 
diseases and there is some evidence that treatment with ribo-
ﬂ  avin can provide some beneﬁ  t against diseases associated 
with oxidative stress (Bonnefont-Rousselot 2004; Manthey 
et al 2006). 
Another co-factor Thiamine (Vitamin B1) has been 
investigated for its role in the treatment of oxidative 
stress-related diseases. Thiamine diphosphate is the active 
form of thiamine and it serves as a co-factor for several 
enzymes, which are important in the biosynthesis of reduc-
ing equivalents used in oxidant stress defenses (Singleton 
and Martin 2001). Thiamine deﬁ  ciency has been linked 
to the promotion of neurodegeneration and an increase in 
oxidative stress (Gibson and Zhang 2002); however, its 
effectiveness in treating diseases associated with free radi-
cals is still unclear (Bonnefont-Rousselot 2004; Nascimento 
et al 2006). Nicotinamide, the amide form of niacin or 
nicotinic acid is a precursor for both nicotinamide adenine 
dinucleotide (NAD/NADH), and nicotinamide adenine 
dinucleotide phosphate (NADP). It plays an important 
role in energy metabolism, signal transduction, cellular 
injury, aging (Aksoy et al 2006), and shows signiﬁ  cant 
inhibition of oxidative damage induced by ROS (Kamat 
and Devasagayam 1999; Feng et al 2006), however, its 
mechanism of action is unknown.
Carnitine, which transfers long-chain fatty acids across 
the mitochondrial membrane, has also been investigated for 
its property to scavenge free radicals. It has been shown to 
protect mitochondrial membrane damage during the aging 
process in an experimental model (Savitha and Panneer-
selvam 2006), and to display antioxidant properties in the 
prevention of acetic acid- induced colitis (Cetinkaya et al 
2006). It has also been reported to inhibit hepatocarcino-
geneis via improvement of mitochondrial dysfunction in 
an experimental model (Chang et al 2005), and it has been 
reported to improve fatigue symptoms in cancer patients 
(Gramignano et al 2006). 
The biochemical interaction between free radicals, 
antioxidants, and co-factors needs to be considered further 
and results from long-term trials are needed to evaluate the 
safety and beneﬁ  cial role of these in the prevention and treat-
ment of diseases associated with free radicals. A summary of 
mechanisms involved in the prevention of diseases associated 
with aging is represented in Figure 2.
Conclusions
There is now universal agreement that free radicals are involved 
in the physical, biochemical, and pathological changes asso-
ciated with aging. Oxidative damage to proteins, lipids, and 
DNA accumulates and increases with age, and is associated 
with age-related diseases such as cardiovascular disease, 
neurodegenerative diseases, cancer, and diabetes (Rahman 
2003). The human body deals with the pathological effects 
of ROS by utilizing the endogenous antioxidant system (eg, 
enzymes such as superoxide dismutase), and by the ingestion 
of exogenous antioxidants in the diet (eg, ﬂ  avonoids). The 
presence of co-factors is also important for the antioxidants 
to exert optimum effects. If the oxidative stress exceeds the 
protection afforded by antioxidants the aging process and 
some of the diseases associated with it can accelerate. 
According to the World Health Organization 20% of 
the current world population are aged 60 years and life 
expectancy is continuing to increase throughout the world, 
and it is estimated that by 2025 this number will have grown 
to 29% (WHO 2002).
This change in the world population is been accom-
panied by rise in living standards leading to lifestyle and 
behavior changes that are having an adverse impact on 
population health. This increase in older people is likely 
to place greater financial burden on the health services 
and high social costs for individuals and society if not 
managed properly.
Healthy aging involves the interaction between genes, the 
environment and life styles, and in order for the elderly to 
live independently and relatively disease and disability free 
requires that healthy life styles are promoted throughout life. 
The most modiﬁ  able lifestyle factors are physical activity 
and diet, and the elderly population should be encouraged 
to take up physical activity since it has a positive effect on 
decreasing the risk of many diseases associated with old age 
(Peel et al 2005). The elderly should also be encouraged to 
consume a diet rich in antioxidants as there is evidence that 
such a diet especially in combination with a healthy life style 
can lower the rate of all-causes and cause-speciﬁ  c mortal-
ity by more than 50% in the 70–90 years old (Knoops et al Clinical Interventions in Aging 2007:2(2) 232
Rahman
2004), (see Figure 3). Although, some of the evidence that 
certain dietary antioxidants and some co-factors can reduce 
free radical mediated damage and promote healthy aging 
is controversial, the elderly should be encouraged to take 
exogenous antioxidants and co-factors, which have shown 
efﬁ  cacy in scientiﬁ  c studies. However, more controlled 
studies are needed in order to investigate the efﬁ  cacy and 
safety of antioxidants and co-factors, and their mode of 
action especially in the elderly. The scientiﬁ  c community 
has a moral responsibility to ensure the healthy aging of the 
world population.
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